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Abstract
To date, genome-wide association studies (GWAS) have successfully identified tens
of thousands of genetic variants among a variety of traits/diseases, shedding a light on
the genetic architecture of complex diseases. Polygenicity of complex diseases, which
refers to the phenomenon that a vast number of risk variants collectively contribute to
the heritability of complex diseases with modest individual effects, have been widely
accepted. This imposes a major challenge towards fully characterizing the genetic bases
of complex diseases. An immediate implication of polygenicity is that a much larger
sample size is required to detect risk variants with weak/moderate effects. Meanwhile,
accumulating evidence suggests that different complex diseases can share genetic risk
variants, a phenomenon known as pleiotropy. In this study, we propose a statistical
framework for Leveraging Pleiotropic effects in large-scale GWAS data (LPG). LPG
utilizes a variational Bayesian expectation-maximization (VBEM) algorithm, making
it computationally efficient and scalable for genome-wide scale analysis. To demon-
strate the advantage of LPG over existing methods that do not leverage pleiotropy,
we conducted extensive simulation studies and also applied LPG to analyze three au-
toimmune disorders (Crohn’s disease, rheumatoid arthritis and Type 1 diabetes). The
results indicate that LPG can improve the power of prioritization of risk variants
and accuracy of risk prediction by leveraging pleiotropy. The software is available at
https://github.com/Shufeyangyi2015310117/LPG.
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1 Introduction
Genome-wide association studies (GWAS) have reported more than 51,000 single-nucleotide
polymorphisms (SNPs) to be genome-wide significantly associated with complex human phe-
notypes, including quantitative traits and complex diseases (Accession of the GWAS Cat-
alog database https://www.ebi.ac.uk/gwas/ on October, 2017). Although discovery of
these genetic risk variants has advanced our understanding of the genetic architecture of
complex diseases/traits, these variants can explain only a small proportion of phenotypic
variance [Manolio et al., 2009]. For example, while the heritability of human height has been
estimated to be about 70%-80%, the 697 genetic variants found from GWAS analysis of
human height using 253,288 individuals could explain only 20% of the heritability for human
height collectively. A more complete characterization of the genetic architecture of complex
phenotypes remains a significant challenge.
To increase statistical power in a GWAS analysis, newer analytical methods leveraging
pleiotropy have been developed. Pleiotropy, which refers to the phenomenon that a gene
affects multiple phenotypes, was first proposed more than 100 years ago [Wagner and Zhang,
2011]. Since then, there have been an increasing number of human genetics studies reporting
pleiotropic effects in various complex diseases such as autoimmune diseases [Cotsapas et al.,
2011], metabolic disorders [Kraja et al., 2014] and psychiatric disorders [Wang et al., 2015].
Thus, the identification of genetic risk variants in GWAS can be significantly improved
by incorporating pleiotropy into the statistical analysis. Existing statistical methods for
incorporating pleiotropy in GWAS analysis can proceed by conducting joint GWAS analysis
of multiple traits [Zhou and Stephens, 2014, Liu et al., 2016]. However, these methods
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assume that the GWAS data were collected from the same study individuals and cannot
be applied when the GWAS data was collected from different study cohorts. Thus, there
remains a methodology gap to leverage pleiotropy for joint GWAS analysis of multiple traits
when the GWAS data for each trait was collected from different study cohorts. This article
seeks to fill this gap.
In this article, we propose a novel statistical method for Leveraging Pleiotropic effects in
large-scale GWAS (LPG) data that is collected from different studies. LPG provides a statis-
tical framework for the evaluation of local false discovery rate, prediction accuracy and formal
test of pleiotropic effects between two traits. LPG utilizes a variational Bayesian expectation
maximization (VBEM) algorithm, making it computationally efficient for genome-wide anal-
ysis. We conducted extensive simulation studies to evaluate the performance of LPG. We
then applied it to conduct joint analysis of Crohn’s disease, rheumatoid arthritis and type-I
diabetes using data from the Welcome Trust Case Control Consortium (WTCCC) [Burton
et al., 2007]. The simulation studies and real data analysis suggest that LPG can steadily
improve both the prediction accuracy and statistical power of risk variants identification over
single-trait-based methods that do not leverage pleiotropy.
The remainder of this article is organized as follows. In section 2, we introduce the
statistical model and describe the VBEM algorithm used to estimate the parameters in the
model. In section 3, we describe the statistical inference procedure used to evaluate the
local false discovery rate and the prediction accuracy of the identified genetic variants; we
also describe a formal hypothesis test for pleiotropy. In sections 4 and 5, we evaluate the
performance of LPG using simulations and real data analysis of WTCCC data, respectively.
We conclude with discussions in section 6.
3
2 Methods
2.1 Model for quantitative traits
Suppose that we have a GWAS data set {y,X} with n independent samples, where y ∈ Rn
is the vector of quantitative phenotype and X = [x1, . . . ,xp] ∈ Rn×p is the genotype matrix
for n individuals and p SNPs. Without loss of generality, we assume that both X and y have
been centered. We assume the following standard linear model,
y = Xβ + e, (1)
where β = [β1, . . . , βp]
> is a vector of effect sizes and e ∼ N (0, σ2eI) is the random error. Let
the vector of binary variables γ = [γ1, . . . , γp]
> indicate the association status of all p SNPs,
where γj = 1 indicates that the j-th SNP is associated with trait y, and γj = 0 otherwise.
In this paper, we consider a spike-slab prior [Kuo and Mallick, 1998]
y|X,β,γ, σ2e ∼ N
(∑
j
γjβjxj, σ
2
e
)
,with γj ∼ Ber(α), βj ∼ N (0, σ2β), (2)
where Ber(α) is the Bernoulli distribution with probability Pr(γj = 1) = α and N (m,σ2)
denotes the Gaussian distribution with mean m and variance σ2. The model (2) is known
as a binary mask model as we can consider the indicator γj as masking out the coefficient
βj. Then, the probabilistic model can be written as
Pr(y,β,γ|X;θ) = Pr(y|X,β;θ)Pr(β|θ)Pr(γ|θ), (3)
where θ = {σ2β, σ2e , α} is the collection of model parameters.
Now we generalize the above two-groups model to leverage pleiotropy between two traits
that are potentially genetically correlated. Suppose we have two GWAS datasets {y1,X1},
{y2,X2} with n1 and n2 samples, respectively. Here, y1 ∈ Rn1 and y2 ∈ Rn2 are the vectors
of phenotypic values, X1 = [x11, . . . ,x1p] ∈ Rn1×p and X2 = [x21, . . . ,x2p] ∈ Rn2×p are the
4
corresponding genotype matrices for p identical SNPs. Without loss of generality, we assume
that both genotype data (X1 and X2) and phenotype data (y1 and y2) have been centered.
Then we have
yk|Xk,βk,γk, σ2ek ∼ N
(
p∑
j=1
γkjβkjxkj, σ
2
ek
)
,with [γ1j, γ2j] ∼ Mul∈L(α), βkj ∼ N (0, σ2βk),
(4)
where k(= 1, 2) refers to individual studies (hereafter, without further denotation, we take
k to be 1 and 2 by default), βk = [βk1, . . . , βkp]
> is a vector of effect sizes for study k,
σ2ek is the variance for the random error in study k, the vector of binary variables γk =
[γk1, . . . , γkp]
> indicates the association statuses in study k, γ = [γ1,γ2] ∈ Rp×2 is a matrix
for association statuses in two studies, α = (α00, α01, α10, α11)
> is the vector of parameters in
a multinomial distribution, and Mul∈L(α) is the multinomial distribution with parameter α
for each possible values L = {00, 01, 10, 11}, i.e., α00 = Pr(γ1j = 0, γ2j = 0), α10 = Pr(γ1j =
1, γ2j = 0), α01 = Pr(γ1j = 0, γ2j = 1), and α11 = Pr(γ1j = 1, γ2j = 1).
Comparing model (4) with the basic model (2) for a single trait, the major difference lies
in the joint sampling for hidden association statuses in the joint model of two studies. In the
presence of pleiotropy, γ1j and γ2j are no longer independent. We will demonstrate in the
supplementary document, that all the parameters in our model can be adaptively estimated
from the data, without any ad-hoc tuning. Let θ(= {σ2β1 , σ2β2 , σ2e1 , σ2e2 ,α}) be the collection
of model parameters. The joint probabilistic model can be written as
Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ) =
2∏
k=1
(
Pr(yk|Xk,βk,γk;θ)Pr(βk|θ)
)
Pr(γ|θ). (5)
Marginalizing over latent variables (β1,β2,γ1,γ2), the probabilistic model of observed data
becomes
Pr(y1,y2|X1,X2;θ) =
∑
β1,β2,γ1,γ2
Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ), (6)
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where we have abused the operation
∑
to represent integration of continuous variables.
Then, by Bayes rule, the posterior probability distribution for the variables of interest can
be calculated as
Pr(β1,β2,γ1,γ2|y1,y2,X1,X2;θ) = Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)
Pr(y1,y2|X1,X2;θ) . (7)
Computing the posterior distribution (??) is difficult as it requires evaluation of marginal
likelihood (6), which is computationally intractable.
2.2 Algorithm for quantitative trait model
To overcome the intractability of the marginal likelihood (6), we derive an efficient algorithm
based on variational inference, which makes our model scalable to genome-wide data analysis.
The key idea is that we make use of Jensen’s inequality to iteratively obtain an adjustable
lower bound on the marginal log likelihood [Jordan et al., 1999]. First, we have a lower
bound of the logarithm of the marginal likelihood (6),
log Pr(y1,y2|X1,X2;θ) = L(q,θ) +KL(q||p)
≥ Eq[log Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)]− Eq[log q(β1,β2,γ1,γ2)], (8)
where we define
L(q,θ) =
∑
β1,β2,γ1,γ2
q(β1,β2,γ1,γ2) log
p(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)
q(β1,β2,γ1,γ2)
,
KL(q||p) =
∑
β1,β2,γ1,γ2
q(β1,β2,γ1,γ2) log
q(β1,β2,γ1,γ2)
p(β1,β2,γ1,γ2|y1,y2,X1,X2;θ) . (9)
Note that Kullback-Leibler (KL) divergence satisfies KL(q||p) ≥ 0, with equality holds if,
and only if, that variational posterior probability (q) and the true posterior probability (p)
are equal. Similar to expectation-maximization (EM) algorithm, we can maximize the lower
bound L(q,θ) with respect to the variational distribution q, which is equivalent to minimizing
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the KL divergence [Bishop, 2006]. To make it computationally efficient to evaluate the lower
bound, we use mean-field theory [Opper and Saad, 2001] and assume that q(β1,β2,γ1,γ2)
can be factorized as
q(β1,β2,γ1,γ2) =
p∏
j=1
qj(β1j,β2j,γ1j,γ2j). (10)
No additional assumptions on the posterior distribution are required. This factorization (10)
is used as a surrogate for the posterior distribution Pr(β1,β2,γ1,γ2|y1,y2,X1,X2;θ). Using
the properties of factorized distributions in variational inference [Bishop, 2006], we can obtain
the optimal approximation using the following formula:
log qj(β1j, β2j, γ1j, γ2j) = Ej′ 6=j[log Pr(y1,y2,β1,β2,γ1,γ2|X1,X2,θ)] + const (11)
where the expectation is taken with respect to all of the other factors {qj′(β1j′ , β2j′ , γ1j′ , γ2j′)}
for j′ 6= j. After some derivations (details are given in the supplementary document), we
have
q(β1j, β2j, γ1j, γ2j) = f1j(β1j)
γ1jf0(β1j)
1−γ1jf2j(β2j)γ2jf0(β2j)1−γ2j
∏
l
α
1(γ1k=l1,γ2k=l2)
lj , (12)
where αlj is the posterior probability of [γ1j, γ2j] = l, f0(βkj) is the posterior distribution of
βkj when γkj = 0, fkj(βkj) is the posterior distribution of βkj under γkj = 1. With some
algebra, it is easy to show that f0(βkj) and fkj(βkj) are the density functions of Gaussian
distributions N (0, σ2βk) and N (µkj, s2kj). The derivation details on the updating equations
and corresponding VBEM algorithm (Algorithm S1) can be found in the supplementary
document. The VBEM algorithm performs similarly to coordinate descent algorithm, which
comes from the factorization of variational distribution (12). Hence, VBEM algorithm de-
veloped here is scalable to ultra-high dimensions.
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2.3 Accommodating case-control data
Suppose that we have two GWAS case-control datasets {y1,X1,Z1} and {y2,X2,Z2} with
n1 and n2 samples, respectively. All other definitions are identical to those introduced in
Section 2.1 except that yk ∈ Rnk×1 is the vector for disease status taking values -1 and
1 for controls and cases, respectively, and Zk = [zk1, . . . , zkp0 ] ∈ Rnk×p0 is a matrix for p0
covariates in study k. Note that the first column of Zk is a vector of ones corresponding to
an intercept. Then conditional on observed genotype Xk, hidden status γ, and effects βk,
we have
yk|Xk,Zk,βk,γk,φk ∼ Ber(δk), (13)
where δk = [δk1, . . . , δknk ]
>, δki
(
= Pr(yki = 1|X,βk,γk) = 11+e−ykiηki
)
is the sigmoid function
of linear predictor ηki, i is the index for individuals, ηk(= [ηk1, . . . , ηknk ]
> ∈ Rnk×1) is the
linear predictor of the all individuals in study k such that ηk =
∑p0
j=1 zkjφkj+
∑p
j=1 γkjβkjxkj.
Here, we include fixed-effect covariates in the binary studies to adjust potential population
stratification and confounders in samples. β and γ are effect sizes and indicator variables as
defined in Section 2.1. Let θ = {σ2β1 , σ2β2 ,φ1,φ2,α} be the collection of model parameters.
The probabilistic model can be written as
Pr(y1,y2,β1,β2,γ1,γ2|X1,Z1,X2,Z2;θ) =
2∏
k=1
(
Pr(yk|Xk,Zk,βk,γk;θ)Pr(βk|θ)
)
Pr(γ|θ).
(14)
Note that we take coefficients for covariates (Z1 and Z2) as fixed effects, which are included
in parameter space θ. Marginalizing over latent variables (β1,β2,γ1,γ2), we can get the
marginal likelihood similar to expression (6). The primary difficulty for the binary model
(14) comes from the evaluation of sigmoid function δki. As there is no convenient conjugate
prior for sigmoid function, it is not analytically feasible to compute the full posterior over
the parameter space. To overcome this limitation,, we use the Bohning bound [Bo¨hning,
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1992]. Here, we first derive a lower bound of the complete-data likelihood as follows
Pr(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2,θ)
≥
(
2∏
k=1
B(yk|Xk,Zk,βk,γk;θ)Pr(βk;θ)
)
Pr(γ;θ)
=h(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2; θ˜),
(15)
whereB(yk|Xk,Zk,βk,γk; θ˜)
(
=
∏nk
i=1 exp(−12aη2kiy2ki + (1 + bki)ηkiyki − cki)
)
denotes the prod-
uct of lower bound of sigmoid functions with a = 1/4, bkn = aψkn − (1 + e−ψkn)−1 and
ckn =
1
2
aψ2kn − (1 + e−ψkn)−1ψkn + log(1 + eψkn), and θ˜ = {σ2β1 , σ2β2 ,φ1,φ2,α,ψ1,ψ2} is the
new parameter which combines the model parameters θ with variational parameters ψ1,ψ2
(details are provided in the supplementary document). Using Jensen’s inequality and the
lower bound of complete-data likelihood (15), we have the following lower bound
log Pr(y1,y2|X1,X2,Z1,Z2,θ)
= log
∑
β1,β2,γ1,γ2
Pr(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2,θ)
≥ log
∑
β1,β2,γ1,γ2
h(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2,θ)
≥Eq[log h(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2; θ˜)]− Eq[log q(β1,β2,γ1,γ2)]
:=L(q),
(16)
where the first inequality is based on Bohning bound and the second one follows from Jensen’s
inequality as in lower bound (8). By maximizing the lower bound (16) with respect to µkj
and s2kj, we can again obtain the variational distribution in the same fashion as expression
(12). Details of updating equations and corresponding VBEM algorithm (Algorithm S2) are
given in supplementary document.
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3 Statistical inference
3.1 Evaluation of local false discovery rate (lfdr)
After fitting an LPG model with all the parameters estimated, SNPs can be prioritized based
on their local false discovery rates (lfdr) [Efron, 2012]. As discussed in Efron et al. [2008], al-
though false discovery rate (FDR) methods were developed in a strict frequentist framework,
they also have a convincing Bayesian rationale. Since
∑
l∈Lk αlj is a good approximation to
the true posterior Pr(γkj = 1|y1,y2,X1,X2;θ), lfdrkj(= 1 −
∑
l∈Lk αlj) can be used as lfdr
of SNP j in the k-th trait, where k = 1 or 2, L1 = {10, 11} and L2 = {01, 11}. Namely,
the smaller the lfdr, the more we are confident in prioritizing a SNP. Then we use the direct
posterior probability approach [Newton et al., 2004] to control global false discovery rate to
select a list of SNPs to be as large as possible while bounding the rate of false discoveries
by a pre-specified threshold τ . In details, with data and fitted model in hand, we rank the
SNPs according to their local false discovery rate in the ascending order. We can increase
the threshold for lfdr ζ from zero to one and find the largest ζ that satisfies
F̂DR(τ) =
∑p
j=1 l̂fdrkjI
[
l̂fdrkj ≤ ζ
]
∑p
j=1 I
[
l̂fdrkj ≤ ζ
] ≤ τ, (17)
where τ is a pre-specified bound of global FDR, I(·) is the indicator function which returns
1 if the argument is true, 0 otherwise. By doing so, it is convenient for users to control FDR
either in terms of global FDR or lfdr.
3.2 Evaluation of prediction performance
In addition to the identification of risk variants, we can also use the LPG approach to conduct
risk prediction. In the LPG model, the effect size of SNP j in the k-th study is given as
E(γkjβkj) =
∑
l∈Lk αljµkj. Given the genotype vector of an individual x = [x1, . . . , xp]
>,
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the predicted phenotypic value is yˆk = ck0 +
∑
j
(
(xkj − ckj)
∑
l∈Lk αljµkj
)
, where ck0 and
ck1, . . . , ckp are the mean of the phenotype and each SNP before centering for the k-th study,
respectively. We measured Pearson’s correlation between the observed phenotypic values and
predicted phenotypic values in the testing set for quantitative trait. For case-control studies,
predicted linear predictor is ηˆk = zkφk +
∑
j
(
(xkj − ckj)
∑
l∈Lk αljµkj
)
and odds of being a
case for such an individual can be found by logit transformation. For the predicted odds
from the testing set, we can evaluate the area under the receiver operating characteristic
(ROC) curve (AUC) [Fogarty et al., 2005].
3.3 Hypothesis testing of pleiotropy
It is of great interest to quantify the significance of pleiotropy between two traits. Based
on the definition of pleiotropy, the presence of pleiotropy means that the null and non-null
groups in two traits are not distributed independently. Formally, we can set up a likelihood
ratio test (LRT) as follows:
H0 : α11 = α1∗α∗1, vs. Ha : α11 6= α1∗α∗1 (18)
where α1∗ = α10 +α11 and α∗1 = α01 +α11 are marginal probability. Clearly, a LRT statistic
is
λ = 2
(
log Pr(y1,y2|X1,X2; Θ̂)− log Pr(y1,y2|X1,X2; Θ̂0)
)
, (19)
where Θ̂0 and Θ̂ denote the parameters estimated under the null and alternative hypotheses
respectively. Due to the intractability of marginal distribution (6), we use the lower bound
as a surrogate to approximate the marginal likelihood. Under the null hypothesis, the test
statistic λ approximately follows a χ2 distribution with df = 1.
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4 Simulation studies
In this section, we evaluated the performance of LPG approach described in the Section 2
using simulation studies. We examined its performance in risk variants identification as
measured by AUC, statistical power and FDR and risk prediction as measured by Pearson’s
correlation and AUC for quantitative traits and binary traits, respectively. We compared
its performance with two other methods that do not leverage pleiotropy, including the two-
groups model (BVSR [Guan and Stephens, 2011]) and Lasso [Friedman et al., 2010]. The
number of replicates in simulation studies was 100 for all settings.
4.1 Simulation settings
The simulation data sets were generated as follows. The genotype matrices Xk (k = 1, 2)
were first simulated from normal distribution, where autoregressive correlation (AR) ρ|j−j
′|
was set to mimic the linkage disequilibrium(LD) between variants j and j′ with ρ = 0.2,
0.5 and 0.7. Next, the entries of both Xk (k = 1, 2) were discretized to numerically coded
genotypes {0, 1, 2} according to the Hardy-Weinberg equilibrium based on the minor allele
frequencies, which were drawn from a uniform distribution on [0.05, 0.5]. In all scenarios, the
sample sizes for each study were set to nk = 3, 000 (k = 1, 2) and the number of variants were
set to p = 20, 000. To evaluate prediction performance, we generated additional ntest = 500
samples for each study under the same model. Denote the proportions of the null and non-
null SNPs of both GWAS as α0 and α1, respectively. Then the hidden association status
in first study (γ1) could be sampled randomly with the number of nonzero entries – pα1.
α1 is set to 0.005 for the quantitative traits and 0.0025 for the binary traits. To account
pleiotropy between two GWAS, we controlled the number of SNPs with pleiotropic effects as
pα1(α1 + gα0). Clearly, g = 0 and g = 1 refer to two extreme cases – no pleiotropy and full
pleiotropy, respectively. We considered g = 0 to 1 equally spaced by 0.2. Next, effect sizes
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β were simulated from N (0, 1). For the quantitative trait, as heritability of each study is
defined as h2k =
Var(Xkβkγk)
Var(Xkβkγk)+σ2ek
, the noise level was chosen to control heritability at 0.3, 0.4
and 0.5. For the binary trait, we set population prevalence to be 0.1 and case-control ratio
to be 0.5 while controlling heritability at 0.3, 0.4 and 0.5 using liability model [Lee et al.,
2011].
4.2 Simulation results
For both the quantitative and binary traits, we analyzed the simulated data using the pro-
posed LPG jointly on two traits in comparison with other alternative methods, including
BVSR and Lasso on each separate trait. For probabilistic approaches, LPG and BVSR,
we evaluated their performance of risk variants identification using the area under the re-
ceiver operating characteristic (ROC) curve (AUC), statistical power, and false discovery
rate (FDR). Note that for all settings, we evaluated statistical power to identify risk variants
under the global FDR controlled at 0.2. As Lasso is a deterministic approach and FDR is not
controllable, there are no points to evaluate their statistical power. The tuning parameter
in Lasso was chosen by using 5-fold cross-validation [Friedman et al., 2001]. We evaluated
the performance of risk prediction measured by Pearson’s correlation between the observed
phenotypic values and the predicted values in testing sets for the quantitative trait while
AUC was used to measure the performance of classification accuracy for case-control studies.
For the quantitative traits, Figure 1 shows the performance of risk variants identification
and prediction under ρ = 0.5 and h2 = 0.5. It demonstrates that LPG incorporating the
pleiotropy between two traits can actually improve the risk SNP identification over two-
groups model (BVSR) in general. In particular, when there is no pleiotropy (g=0), the
performance of LPG is the same as two-groups model (BVSR) suggesting that LPG can
explore available pleiotropic information automatically. Another observation is that the
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performance of risk SNP identification (AUC and statistical power) of LPG improves in
the ascending trend with the proportion of shared risk SNPs. Additionally, probablistic
approaches (LPG and BVSR) outperform the Lasso in terms of risk SNP identification in
the presence of pleiotropy or not as Lasso does not leverage pleiotropy between two traits
and its performance depends on the extend of sparsity and strong signals. The FDR of
both probabilistic models (LPG and BVSR) is well controlled by our target, 0.2. In terms of
prediction performance, as pleiotropy becomes stronger, the Pearson’s correlation coefficients
between the observed and predicted phenotypic values in LPG increase slightly over the
BVSR. For the binary traits, the results with similar patterns are shown in Figure 2 under
ρ = 0.5 and h2 = 0.5. First, the improved AUC and statistical power of LPG are in the
ascending order of the strength of pleiotropy while global FDR of LPG and BVSR is well
under control. The prediction performance of LPG slightly improves over the BVSR when
pleiotropy is strong. In our simulation studies, we found the performance of Lasso is worse
than its probabilistic counter part, BVSR. The similar pattern can be found in [Dai et al.,
2017]. More simulation results under different settings (Tables S1 and S2) are shown in
Figures S1 - S18 in the supplementary document.
We evaluated the type 1 error and power of the hypothesis test for pleiotropy. As shown
in Figure S19 in the supplementary document, the power increases with the ascending trend
of pleiotropy (g) and the similar performance among different ρ for both the quantitative
and binary traits can be found there. Type 1 error for different choice of ρ is shown in Figure
S20 in the supplementary document. One can find that type 1 error is a little conservative
for both the quantitative and binary traits.
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5 Real data analysis
Crohn’s disease (CD), rheumatoid arthritis (RA) and type-I diabetes (T1D) are autoimmune
diseases and previous work suggests they can share common genetic risk variants [Solovieff
et al., 2013]. We applied LPG for the analysis of CD, RA and T1D uisng data reported by
the Welcome Trust Case Control Consortium (WTCCC) [Burton et al., 2007]. The dataset
consists of approximately 2,000 cases for all CD, RA and T1D and 3,000 shared controls, with
genotypes at 500,568 SNPs. We performed strict quality control data using plink [Purcell
et al., 2007]. First, we removed individuals with missing genotypes call-rates greater than 2%.
For cases from each disease and samples from each control data set, we removed SNPs with
minor allele frequencies smaller than 5% and SNPs with missing rate greater than 1%. We
further excluded SNPs with p-value < 0.001 in Hardy-Weinberg equilibrium test for samples
in control groups. In addition, pairs of subjects with estimated relatedness exceeding 0.025%
were identified and one individual from each pair was removed at random by GCTA [Yang
et al., 2011].
5.1 RA and T1D
Since WTCCC used shared controls among seven diseases and samples in the control group
were from two cohorts (the 1958 British Birth Cohort (58C) and UK Blood Services (UKBS)),
we used one control cohort for RA and the other for T1D. After quality control filtering,
240,101 SNPs in 1,812 cases from RA, 1,932 cases from T1D, and 2,897 controls from two
data sets were retained for the following analysis. First, we conducted the analysis for 58C
controls with RA and UKBS controls with T1D using LPG and BVSR. The prioritization
results are shown in Figure 3 in addition to a complete list of findings in Table 1, in which
the cut off point is 0.2 in terms of lfdr. As shown in Table 2, LPG identified slightly
more SNPs than these from BVSR. The estimated proportions were αˆ00 = 0.9999, αˆ01 =
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1.488 × 10−10, αˆ10 = 1.499 × 10−18, αˆ11 = 5.209 × 10−05 and p-value for the pleiotropy test
was 1.68× 10−17 suggesting the existence of pleiotropy between RA and T1D. In summary,
leveraging the pleiotropic effects enabled LPG to identify more risk SNPs over the single-trait
analysis (BVSR). For example, rs6679677 within PTPN22 gene and rs9272346 within MHC
region exhibited higher significance using the joint analysis of LPG, which was previously
reported [Burton et al., 2007]. In addition, T1D-associated SNP rs9272346 was also found
to be associated with RA in Pakistani patients [Kiani et al., 2015], rs10484565 within TAP2
gene was shown to confer risk enriched in the RA group [Lee et al., 2008], and rs241427 near
TAP1/TAP2 was shown to have relatively strong associations in the collective interaction
analysis of RA and T1D [Woo et al., 2017]. We also evaluated the prediction performance
using RA and T1D. Specifically, we quantitatively assessed the performance of risk prediction
using 10-fold cross validation. The prediction accuracy of both LPG and BVSR is shown in
Table 2. Clearly, it shows that the joint analysis of RA and T1D consistently outperformed
the separate analysis of each study in terms of prediction accuracy, which improved from
62.8% to 64.4% for RA and from 76.7% to 78.3% for T1D as shown in Table 2. It took
around 7 minutes to finish the joint analysis as shown in Table S3 in the supplementary
document. To demonstrate the robustness of our LPG, we switched the control cohorts for
RA and T1D and conducted the same analysis again and the results were similar.
5.2 CD and T1D
After the basic quality control filtering as described above, 240,393 SNPs remained in 1,675
cases from CD, 1,932 cases from T1D, and 2,895 controls from two data sets were used for
analysis. After excluding the MHC region SNPs, leaving us a total of 239,931 SNPs, we
performed the same four comparisons. Here we are presenting the one with 58C controls
for CD and UKBS controls for T1D by excluding MHC region. The Manhattan plots are
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shown in Figure S33 and all SNP findings are shown in Table S17 in the supplementary
document, where the threshold for lfdr is set to 0.2. Obviously, the LPG identified slightly
more risk SNPs than these from two-groups model (BVSR). The estimated proportions were
αˆ00 = 0.9999, αˆ01 = 4.477× 10−5, αˆ10 = 2.058× 10−9 and αˆ11 = 3.898× 10−05, and p-values
for the pleiotropy test was 2.96×10−2 suggesting the existence of pleiotropy between CD and
T1D. For example, rs11805303 in the IL23R gene was identified to be strongly associated
with CD, which was previously reported [Buzdugan et al., 2016]. Another intergenic SNP
rs2542151 identified by LPG was also reported to be significantly associated with CD [Parkes
et al., 2007]. Besides, rs17234657 on chromosome 5 was identified to be associated with CD
by both LPG and BVSR, which was also previously reported in [Burton et al., 2007]. The
prediction performance of both LPG and BVSR is shown in Table S16 in the supplementary
document. The results demonstrate that the prediction of the jointly analysis of CD and
T1D was slightly better than the separate analysis of each study, which improved from 58.1%
to 58.7% for CD and from 60.1% to 60.3% for T1D. The rest results of other comparisons
are detailed in the supplementary document and they were similar to the one we presented
here.
6 Conclusion
In this article, we proposed a novel statistical framework for leveraging pleiotropy in GWAS
data. Compared with a single-trait-based analysis that does not leverage pleiotropy, LPG
offers improved statistical power and prediction accuracy in the identification of risk variants.
In this article, an efficient algorithm based on VBEM was developed, which not only enables
us to evaluate the posterior quantities of interest, but also makes it scalable to ultra-high
dimensions. These advantages make LPG a powerful tool to analyze GWAS data exhibiting
pleiotropic effects. In this article, we analyzed two pairs of traits from WTCCC, namely,
17
RA vs T1D and CD vs T1D. The findings are consistent with the recent advances in biology
and genetics.
Despite these advantages, modelling pleiotropic effects in a combinatorial fashion limits
the usage of LPG to no more than two traits as the number of hidden association status
increases exponentially with the number of traits. This feature limits the use of LPG for
analysis of two traits. LPG was designed to leverage pleiotropy when GWAS data for mul-
tiple traits is collected in different study individuals and complements the earlier methods
proposed for incorporating pleiotropy when GWAS data is collected in the same study indi-
viduals [Zhou and Stephens, 2014, Liu et al., 2016]. However, to date no method has been
proposed for leveraging pleiotropy when the GWAS data for multiple traits is collected from
partially shared study samples, and is an avenue for future work.
7 Acknowledgement
This work was supported in part by grant NO. 61501389 from National Science Funding of
China, grants No.22302815, NO. 12316116 and NO. 12301417 from the Hong Kong Research
Grant Council, and grant R-913-200-098-263 from Duke-NUS Graduate Medical School, and
AcRF Tier 2 (MOE2016-T2-2-029) from Ministry of Eduction, Singapore.
18
Figure 1: The comparison of LPG (VB joint) with its alternative methods, BVSR (VB sep-
arate) and Lasso, for quantitative traits demonstrated the increased power in the ascending
order of pleiotropy g while FDR of both LPG and BVSR were controlled at 0.2. Panels
from top to bottom are AUC, FDR, Power and Prediction, respectively. Choices of g range
from 0 to 1. The parameter setting of the model is : p = 20,000, n1 = n2 = 3000, h
2 = 0.5,
ρ = 0.5, α1 = 0.005.
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Figure 2: The comparison of LPG (VB joint) with its alternative methods, BVSR (VB
separate) and Lasso, for binary traits demonstrated the increased power in the ascending
order of pleiotropy g while FDR of both LPG and BVSR were controlled at 0.2. Panels
from top to bottom are AUC, FDR, Power and Prediction, respectively. Choices of g range
from 0 to 1. The parameter setting of the model is : p = 20,000, n1 = n2 = 3000, h
2 = 0.5,
ρ = 0.5, α1 = 0.0025.
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Figure 3: For the data consisting of 58C controls with RA and UKBS controls with T1D,
manhattan plots of separate analysis using BVSR and joint analysis using LPG.
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1 Simulation studies: Quantitative trait
For the quantitative trait, we conducted simulation studies to evaluate the performance of
FGP with its alternative, i.e. BVSR and Lasso. We first evaluated their performance of the
identification of risk variants using AUC, statistical power, and FDR. Note that we can only
evaluate AUC for Lasso and FDR was controlled at 0.2. We then evaluated the prediction
performance by measuring the Pearson’s correlation between observed phenotypic values and
estimated phenotypic values in a testing set for all three methods. The number of replicates
in simulation studies was 50 for all settings. The results are provided in Figure S1-S9 and
they demonstrate that the performance of FGP gradually gets better as the pleiotropic effects
become stronger.
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Figure S1: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.3, ρ = 0.2, α1 = 0.005.
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Figure S2: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.3, ρ = 0.5, α1 = 0.005.
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Figure S3: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.3, ρ = 0.7, α1 = 0.005.
7
Figure S4: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.4, ρ = 0.2, α1 = 0.005.
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Figure S5: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p = 20,
000, n1 = n2 = 3000, h
2 = 0.4, ρ = 0.5, α1 = 0.005.
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Figure S6: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.4, ρ = 0.7, α1 = 0.005.
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Figure S7: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.5, ρ = 0.2, α1 = 0.005.
11
Figure S8: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.5, ρ = 0.5, α1 = 0.005.
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Figure S9: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso for different
choice g ranging from 0 to 1 for quantitative trait. Panels from top to bottom are AUC,
FDR, Power and Prediction, respectively. The parameter setting of the model is : p =
20,000, n1 = n2 = 3000, h
2 = 0.5, ρ = 0.7, α1 = 0.005.
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2 Simulation studies: Binary trait
For the binary trait in case-control studies,we conducted simulation studies to evaluate the
performance of FGP with its alternative, i.e. BVSR and Lasso. We first evaluated their
performance of the identification of risk variants using AUC, statistical power, and FDR.
Note that we can only evaluate AUC for Lasso and FDR was controlled at 0.2. Thirdly,
we measure the proportion of true risk SNPs discovered by Power. We then evaluated the
prediction performance in a testing set using AUC as described in Section 3.2 for all three
methods The results are provided in Supplementary Figure S10-S18 and they demonstrate
that the performance of FGP gradually gets better as the pleiotropic effects become stronger.
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Figure S10: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.3, ρ = 0.2, α1 = 0.0025.
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Figure S11: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.3, ρ = 0.5, α1 = 0.0025.
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Figure S12: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.3, ρ = 0.7, α1 = 0.0025.
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Figure S13: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.4, ρ = 0.2, α1 = 0.0025.
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Figure S14: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.4, ρ = 0.5, α1 = 0.0025.
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Figure S15: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.4, ρ = 0.7, α1 = 0.0025.
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Figure S16: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.5, ρ = 0.2, α1 = 0.0025.
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Figure S17: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.5, ρ = 0.5, α1 = 0.0025.
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Figure S18: Comparison of FGP (VB joint), BVSR (VB separate), and Lasso with different
g ranging from 0 to 1 for binary trait. Panels from top to bottom are AUC, FDR, Power
and Prediction, respectively. The parameter setting of the model is : p = 20,000, n1 = n2 =
3000, h2 = 0.5, ρ = 0.7, α1 = 0.0025.
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Figure S19: Power of pleiotropy test for both quantitative (left panel) and binary (right
panel) trait. ρ is chosen to be 0.2, 0.5, 0.7, h2 is 0.5 and the pleiotropy parameter g is
controlled at 0.1, 0.2, 0.3. The number of replicates is 100.
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Figure S20: Type I error of pleiotropy test for quantitative (left panel) and binary (right
panel) trait. ρ is chosen to be 0.2, 0.5, 0.7 and h2 is 0.5. The number of replicates is 500.
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3 Real data analysis
iter-sep1 time-sep1(s) iter-sep2 time-sep2(s) iter-joint time-joint(s)
RA-T1D-inMHC 69 271.70 27 139.88 69 713.53
T1D-RA-inMHC 29 72.98 66 167.67 75 451.86
RA-T1D-exMHC 160 540.37 100 403.49 175 1736.89
T1D-RA-exMHC 106 374.78 134 522.26 178 1441.98
CD-T1D-inMHC 177 427.43 27 73.75 305 1778.91
T1D-CD-inMHC 27 128.62 183 583.80 237 2187.62
CD-T1D-exMHC 177 372.41 101 263.57 217 1170.94
T1D-CD-exMHC 107 319.80 183 422.41 220 1366.07
Table S3: Summary of real data analysis, inMHC and exMHC mean SNPs include and ex-
clude MHC region, respectively, iter-sep1 and iter-sep2 mean iterations of separate analysis
using BVSR for first and second study, respectively, iter-joint means iterations of joint anal-
ysis using FGP, time-sep1 and time-sep2 mean time of separate analysis using BVSR for
first and second study, respectively, time-joint means time of joint analysis
3.1 Comparison of FGP and BVSR for the data consisting of 58C
controls with T1D and UKBS controls with RA
Figure S21: For the data consisting of 58C controls with T1D and UKBS controls with RA,
manhattan plots of separate analysis using BVSR and joint analysis using FGP.
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Figure S22: For the data consisting of 58C controls with T1D and UKBS controls with RA,
prediction performance of separate analysis using BVSR and joint analysis using FGP.
Data number of hits prediction accuracy(AUC)
1 Rheumatoid arthritis(RA)joint 11 63.2%(2.5%)
2 Type 1 diabetes(T1D)joint 11 75.7%(2.2%)
3 Rheumatoid arthritis(RA)separate 3 60.9%(2.8%)
4 Type 1 diabetes(T1D)separate 10 75.2%(2.8%)
Table S4: For the data consisting of 58C controls with T1D and UKBS controls with RA,
summary of separate and joint analysis of RA and T1D
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snp chr position sep RA(fdr) sep T1D(fdr) joi RA(fdr) joi T1D(fdr)
1 rs6679677 1 114303808 2.5e-11* 0e+00* 0e+00* 0e+00*
2 rs13200022 6 31098957 1e+00 5.77e-06* 1.82e-09* 1.37e-14*
3 rs3130484 6 31715882 1e+00 8.35e-06* 1e+00 1e+00
4 rs2075800 6 31777946 6.91e-14* 1e+00 1e+00 1e+00
5 rs550513 6 31920687 9.88e-01 1e+00 6.3e-06* 6.3e-06*
6 rs3130287 6 32050544 1e+00 0e+00* 2.79e-08* 1.11e-16*
7 rs17421624 6 32066177 1e+00 1e+00 2.22e-16* 1.11e-16*
8 rs9272346 6 32604372 1.14e-03* 0e+00* 1.03e-11* 0e+00*
9 rs2070121 6 32781554 1e+00 1.22e-11* 2.22e-16* 0e+00*
10 rs10484565 6 32795032 9.97e-01 1.55e-15* 0e+00* 0e+00*
11 rs241427 6 32804414 1e+00 1.1e-08* 1.24e-09* 1.28e-10*
12 rs12529313 6 32817130 1e+00 7.3e-08* 3.05e-04* 3.05e-04*
13 rs11171739 12 56470625 1e+00 2.61e-04* 1.63e-03* 1.63e-03*
Table S5: For the data consisting of 58C controls with T1D and UKBS controls with RA,
list of SNPs of two modes: separate analysis and joint analysis. * denotes the local fdr <0.2,
sep means separate, joi means joint.
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3.2 Comparison of FGP and BVSR for the data consisting of 58C
controls with T1D and UKBS controls with RA exclude MHC
region
Figure S23: For the data consisting of 58C controls with T1D and UKBS controls with
RA exclude MHC region SNPs, manhattan plots of separate analysis using BVSR and joint
analysis using FGP.
Figure S24: For the data consisting of 58C controls with T1D and UKBS controls with RA
exclude MHC region SNPs, prediction performance of separate analysis using BVSR and
joint analysis using FGP.
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Data number of hits prediction accuracy(AUC)
1 Rheumatoid arthritis(RA)joint 2 56.7%(2.9%)
2 Type 1 diabetes(T1D)joint 3 58.4%(2.8%)
3 Rheumatoid arthritis(RA)separate 1 52.5%(2.1%)
4 Type 1 diabetes(T1D)separate 3 58.8%(2.9%)
Table S6: For the data consisting of 58C controls with T1D and UKBS controls with RA
exclude MHC region, summary of separate and joint analysis of RA and T1D
snp chr position sep RA(fdr) sep T1D(fdr) joi RA(fdr) joi T1D(fdr)
1 rs6679677 1 114303808 6.61e-11* 6.66e-15* 6.66e-16* 1.11e-16*
2 rs11171739 12 56470625 1e+00 5.1e-03* 6.42e-01 1.48e-02*
3 rs17696736 12 112486818 1e+00 1.26e-03* 1.03e-01* 4.85e-04*
Table S7: For the data consisting of 58C controls with T1D and UKBS controls with RA
exclude MHC region, list of SNPs of two modes: separate analysis and joint analysis. *
denotes the local fdr <0.2, sep means separate, joi means joint.
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3.3 Comparison of FGP and BVSR for the data consisting of 58C
controls with RA and UKBS controls with T1D exclude MHC
region
Figure S25: For the data consisting of 58C controls with RA and UKBS controls with T1D
exclude MHC region SNPs, manhattan plots of separate analysis using BVSR and joint
analysis using FGP.
Figure S26: For the data consisting of 58C controls with RA and UKBS controls with T1D
exclude MHC region SNPs, prediction performance of separate analysis using BVSR and
joint analysis using FGP.
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Data number of hits prediction accuracy(AUC)
1 Type 1 diabetes(T1D)joint 3 59.1%(2.1%)
2 Rheumatoid arthritis(RA)joint 1 56.7%(2.6%)
3 Type 1 diabetes(T1D)separate 3 59.8%(2.2%)
4 Rheumatoid arthritis(RA)separate 1 56.4%(2.7%)
Table S8: For the data consisting of 58C controls with RA and UKBS controls with T1D
exclude MHC region, summary of separate and joint analysis of T1D and RA
snp chr position sep T1D(fdr) sep RA(fdr) joi T1D(fdr) joi RA(fdr)
1 rs6679677 1 114303808 3.78e-13* 7.34e-13* 0e+00* 0e+00*
2 rs2292239 12 56482180 1.65e-02* 1e+00 2.82e-02* 8.81e-01
3 rs17696736 12 112486818 4.95e-06* 1e+00 5.5e-06* 5.96e-01
Table S9: For the data consisting of 58C controls with RA and UKBS controls with T1D
exclude MHC region, list of SNPs of two modes: separate analysis and joint analysis. *
denotes the local fdr <0.2, sep means separate, joi means joint.
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3.4 Comparison of FGP and BVSR for the data consisting of 58C
controls with T1D and UKBS controls with CD
Figure S27: For the data consisting of 58C controls with T1D and UKBS controls with CD,
manhattan plots of separate analysis using BVSR and joint analysis using FGP.
Figure S28: For the data consisting of 58C controls with T1D and UKBS controls with CD,
prediction performance of separate analysis using BVSR and joint analysis using FGP.
33
Data number of hits prediction accuracy(AUC)
1 Crohn’s disease(CD)joint 3 57.6%(3.7%)
2 Type 1 diabetes(T1D)joint 10 75.6%(2.8%)
3 Crohn’s disease(CD)separate 3 57.4%(3.6%)
4 Type 1 diabetes(T1D)separate 10 75.7%(2.8%)
Table S10: For the data consisting of 58C controls with T1D and UKBS controls with CD,
summary of separate and joint analysis of CD and T1D
snp chr position sep CD(fdr) sep T1D(fdr) joi CD(fdr) joi T1D(fdr)
1 rs6679677 1 114303808 1e+00 0e+00* 9.98e-01 0e+00*
2 rs10210302 2 234158839 1.1e-01* 1e+00 1.1e-01* 9.99e-01
3 rs9292777 5 40437948 1.45e-04* 1e+00 1.45e-04* 1e+00
4 rs13200022 6 31098957 1e+00 5.58e-06* 1e+00 5.57e-06*
5 rs3130484 6 31715882 1e+00 2.06e-05* 1e+00 2.06e-05*
6 rs3130287 6 32050544 1e+00 0e+00* 9.98e-01 0e+00*
7 rs9272346 6 32604372 1e+00 0e+00* 9.98e-01 1.11e-16*
8 rs2070121 6 32781554 1e+00 1.23e-11* 1e+00 1.21e-11*
9 rs10484565 6 32795032 1e+00 1.55e-15* 1e+00 1.44e-15*
10 rs241427 6 32804414 1e+00 1.29e-08* 1e+00 1.29e-08*
11 rs12529313 6 32817130 1e+00 7.63e-08* 1e+00 7.59e-08*
12 rs11171739 12 56470625 1e+00 2.61e-04* 1e+00 2.61e-04*
13 rs2066843 16 50745199 8.8e-06* 1e+00 8.81e-06* 1e+00
Table S11: For the data consisting of 58C controls with T1D and UKBS controls with CD,
list of SNPs of two modes: separate analysis and joint analysis. * denotes the local fdr <0.2,
sep means separate, joi means joint.
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3.5 Comparison of FGP and BVSR for the data consisting of 58C
controls with CD and UKBS controls with T1D
Figure S29: For the data consisting of 58C controls with CD and UKBS controls with T1D,
manhattan plots of separate analysis using BVSR and joint analysis using FGP.
Figure S30: For the data consisting of 58C controls with CD and UKBS controls with T1D,
prediction performance of separate analysis using BVSR and joint analysis using FGP.
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Data number of hits prediction accuracy(AUC)
1 Type 1 diabetes(T1D)joint 12 76.9%(3.3%)
2 Crohn’s disease(CD)joint 4 57.9%(4.5%)
3 Type 1 diabetes(T1D)separate 10 76.8%(3.2%)
4 Crohn’s disease(CD)separate 3 57.9%(4.7%)
Table S12: For the data consisting of 58C controls with CD and UKBS controls with T1D,
summary of separate and joint analysis of T1D and CD
snp chr position sep T1D(fdr) sep CD(fdr) joi T1D(fdr) joi CD(fdr)
1 rs11805303 1 67675516 1e+00 2.2e-06* 9.45e-01 3.58e-06*
2 rs6679677 1 114303808 0e+00* 1e+00 0e+00* 6.02e-01
3 rs6752107 2 234161448 1e+00 9.06e-05* 9.58e-01 1.81e-04*
4 rs17234657 5 40401509 1e+00 4.14e-02* 9.61e-01 4.96e-02*
5 rs13200022 6 31098957 9.26e-12* 1e+00 0e+00* 8.11e-01
6 rs550513 6 31920687 9.98e-01 1e+00 1.73e-05* 8.28e-01
7 rs3130287 6 32050544 0e+00* 1e+00 -2.22e-16* 5.14e-01
8 rs17421624 6 32066177 9.7e-01 1e+00 1.27e-08* 8.66e-01
9 rs9272346 6 32604372 0e+00* 1e+00 0e+00* 8.94e-01
10 rs2070121 6 32781554 0e+00* 1e+00 6.66e-16* 7.21e-01
11 rs10484565 6 32795032 0e+00* 1e+00 1.11e-16* 8.59e-01
12 rs241427 6 32804414 1.51e-07* 1e+00 1.34e-04* 8.93e-01
13 rs12529313 6 32817130 8.28e-05* 1e+00 9.84e-01 9.98e-01
14 rs10759987 9 121364134 2.15e-03* 1e+00 2.84e-03* 8.92e-01
15 rs17696736 12 112486818 4.87e-05* 1e+00 2.45e-06* 4.93e-01
16 rs2542151 18 12779947 1e+00 8.09e-01 4.59e-02* 2.61e-02*
Table S13: For the data consisting of 58C controls with CD and UKBS controls with T1D,
list of SNPs of two modes: separate analysis and joint analysis. * denotes the local fdr <0.2,
sep means separate, joi means joint.
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3.6 Comparison of FGP and BVSR for the data consisting of 58C
controls with T1D and UKBS controls with CD exclude MHC
region
Figure S31: For the data consisting of 58C controls with T1D and UKBS controls with
CD exclude MHC region SNPs, manhattan plots of separate analysis using BVSR and joint
analysis using FGP.
Figure S32: For the data consisting of 58C controls with T1D and UKBS controls with CD
exclude MHC region SNPs, prediction performance of separate analysis using BVSR and
joint analysis using FGP.
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Data number of hits prediction accuracy(AUC)
1 Crohn’s disease(CD)joint 8 58.6%(4.2%)
2 Type 1 diabetes(T1D)joint 4 58.6%(3%)
3 Crohn’s disease(CD)separate 3 57.4%(4.4%)
4 Type 1 diabetes(T1D)separate 3 58.5%(2.8%)
Table S14: For the data consisting of 58C controls with T1D and UKBS controls with CD
exclude MHC region, summary of separate and joint analysis of CD and T1D
snp chr position sep CD(fdr) sep T1D(fdr) joi CD(fdr) joi T1D(fdr)
1 rs4655679 1 67599657 3.11e-01 1e+00 1.5e-01* 6.45e-01
2 rs6679677 1 114303808 1e+00 6.44e-15* 7.53e-08* 3.33e-15*
3 rs10210302 2 234158839 1.09e-01* 1e+00 6.33e-02* 4.75e-01
4 rs9292777 5 40437948 1.49e-04* 1e+00 2.24e-04* 7.42e-01
5 rs11171739 12 56470625 1e+00 5.13e-03* 1.29e-02* 1.29e-02*
6 rs17696736 12 112486818 1e+00 1.24e-03* 4.76e-05* 4.76e-05*
7 rs2066843 16 50745199 8.5e-06* 1e+00 1.21e-05* 8.3e-01
8 rs2542151 18 12779947 9.69e-01 9.97e-01 3.28e-02* 3.65e-02*
Table S15: For the data consisting of 58C controls with T1D and UKBS controls with CD
exclude MHC region, list of SNPs of two modes: separate analysis and joint analysis. *
denotes the local fdr <0.2, sep means separate, joi means joint.
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3.7 Comparison of FGP and BVSR for the data consisting of 58C
controls with CD and UKBS controls with T1D exclude MHC
region
Figure S33: For the data consisting of 58C controls with CD and UKBS controls with T1D
exclude MHC region SNPs, manhattan plots of separate analysis using BVSR and joint
analysis using FGP.
Figure S34: For the data consisting of 58C controls with CD and UKBS controls with T1D
exclude MHC region SNPs, prediction performance of separate analysis using BVSR and
joint analysis using FGP.
39
Data number of hits prediction accuracy(AUC)
1 Type 1 diabetes(T1D)joint 4 60.3%(2%)
2 Crohn’s disease(CD)joint 7 58.7%(4.1%)
3 Type 1 diabetes(T1D)separate 4 60.1%(2.3%)
4 Crohn’s disease(CD)separate 3 58.1%(4.4%)
Table S16: For the data consisting of 58C controls with CD and UKBS controls with T1D
exclude MHC region, summary of separate and joint analysis of T1D and CD
snp chr position sep T1D(fdr) sep CD(fdr) joi T1D(fdr) joi CD(fdr)
1 rs11805303 1 67675516 1e+00 2.18e-06* 8.17e-01 8.89e-06*
2 rs6679677 1 114303808 3.98e-13* 1e+00 1.44e-13* 2.94e-05*
3 rs6752107 2 234161448 1e+00 9.34e-05* 8.44e-01 2.15e-04*
4 rs17234657 5 40401509 1e+00 4.14e-02* 8.55e-01 7.8e-02*
5 rs10759987 9 121364134 1.88e-01* 1e+00 7.56e-01 7.56e-01
6 rs2292239 12 56482180 1.41e-02* 1e+00 2.27e-02* 2.28e-02*
7 rs17696736 12 112486818 4.17e-06* 1e+00 8.75e-07* 1.6e-05*
8 rs2542151 18 12779947 9.99e-01 8.11e-01 2.49e-02* 1.22e-02*
Table S17: For the data consisting of 58C controls with CD and UKBS controls with T1D
exclude MHC region, list of SNPs of two modes: separate analysis and joint analysis. *
denotes the local fdr <0.2, sep means separate, joi means joint.
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4 Proof detail for Quantitative trait model
To overcome the intractability of marginal likelihood, we derive an efficient algorithm based
on variational inference, which makes our model scalable to genome-wide data analysis. The
key idea is that we make use of Jensen’s inequality to iteratively obtain an adjustable lower
bound on the marginal log likelihood [Jordan et al., 1999]. First, we have a lower bound of
the logarithm of the marginal likelihood,
log Pr(y1,y2|X1,X2;θ) = L(q,θ) +KL(q||p)
≥ Eq[log Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)]− Eq[log q(β1,β2,γ1,γ2)], (S1)
where we define
L(q,θ) =
∑
β1,β2,γ1,γ2
q(β1,β2,γ1,γ2) log
p(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)
q(β1,β2,γ1,γ2)
,
KL(q||p) =
∑
β1,β2,γ1,γ2
q(β1,β2,γ1,γ2) log
q(β1,β2,γ1,γ2)
p(β1,β2,γ1,γ2|y1,y2,X1,X2;θ) . (S2)
Note that Kullback-Leibler (KL) divergence satisfies KL(q||p) ≥ 0 by using Jensen’s inequal-
ity, with equality holds if, and only if, that variational posterior probability (q) and the true
posterior probability (p) are equal. Similar to expectation-maximization (EM) algorithm, we
can maximize the lower bound L(q,θ) with respect to the variational distribution q, which
is equivalent to minimizing the KL divergence [Bishop, 2006]. To make it computationally
efficient to evaluate the lower bound, we use mean-field theory [Opper and Saad, 2001], and
assume that q(β1,β2,γ1,γ2) can be factorized as
q(β1,β2,γ1,γ2) =
p∏
j=1
qj(β1j,β2j,γ1j,γ2j). (S3)
No additional assumption on the posterior distribution is required. This factorization (S3)
is used as a surrogate for the posterior distribution Pr(β1,β2,γ1,γ2|y1,y2,X1,X2;θ).
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Using the properties of factorized distributions in variational inference [Bishop, 2006], we
can obtain the optimal approximation using the following formula:
log qj(β1j, β2j, γ1j, γ2j) = Ej′ 6=j[log Pr(y1,y2,β1,β2,γ1,γ2|X1,X2,θ)] + const (S4)
where the expectation is taken with respect to all of the other factors {qj′(β1j′ , β2j′ , γ1j′ , γ2j′)}
for j′ 6= j. After some derivations, we have
q(β1j, β2j, γ1j, γ2j) = f1j(β1j)
γ1jf0(β1j)
1−γ1jf2j(β2j)γ2jf0(β2j)1−γ2j
∏
l
α
1(γ1k=l1,γ2k=l2)
lj , (S5)
where αlj is the posterior probability of [γ1j, γ2j] = l, f0(βkj) is the posterior distribution of
βkj when γkj = 0, fkj(βkj) is the posterior distribution of βkj under γkj = 1. With some
algebra, it is easy to show that f0(βkj) and fkj(βkj) are the density functions of Gaussian
distributions N (0, σ2βk) and N (µkj, s2kj) with
µkj =
x>kjyk −
∑p
j′ 6=j Ej′ [γkj′βkj′ ]x>kjxkj′
x>kjxkj +
σ2ek
σ2βk
, s2kj =
σ2ek
x>kjxkj +
σ2ek
σ2βk
. (S6)
As discussed in Carbonetto et al. [2012], both s2kj and µkj can be interpreted using a single-
variable linear model yk = xkjβkj + k, i.e. , update for s
2
kj is the posterior variance of effect
βkj and update for µkj is the posterior mean of effect βkj by correcting correlations among
covariates not included in the single-variable model. With some algebra, we can update log
odds of αlj as follows,
A00j = logα00 +
1
2
log σ2β1 +
1
2
log σ2β2 ,
A10j = logα10 +
1
2
log s21j +
1
2
log σ2β2 +
µ21j
2s21j
,
A01j = logα01 +
1
2
log σ2β1 +
1
2
log s22j +
µ22j
2s22j
,
A11j = logα11 +
1
2
log s21j +
1
2
log s22j +
µ21j
2s21j
+
µ22j
2s22j
,
αlj =
exp(Alj)∑
l∈{00,10,01,11} exp(Alj)
. (S7)
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Since we take q(β1,β2,γ1,γ2) as a surrogate to approximate the true posterior probability,
the resulting variational probability (S39) has a nice interpretation. First, the marginal
probability (α10j + α11j) and (α01j + α11j) can be viewed as an approximation of Pr(γ1j =
1|y1,y2,X1,X2;θ) and Pr(γ2j = 1|y1,y2,X1,X2;θ), respectively. Clearly, pair-wise differ-
ence of Alj in expression (S21) is the posterior log odds, e.g. , A10j − A00j = log α10α00 +
1
2
log
s21j
σ2β1
+
µ21j
2s21j
is the posterior log odds of β1j 6= 0. In the case that the j-th SNP is irrele-
vant to the first phenotype (γ1j = 0), the approximated posterior distribution of β1j remains
the same as its prior, i.e. , β1j ∼ N (0, σ2β1). On the contrary, when γ1j = 1, the posterior
distribution becomes N (µ1j, s21j), where µ1j is the posterior expectation of β1j adjusted for
all other variables.
With q(β1,β2,γ1,γ2) given in (S39), we can derive the lower bound analytically. Once
we have variational lower bound, other parameters can be updated by maximizing the lower
bound while keeping variational distribution q fixed:
σ2ek =
1
nk
(
‖yk −
p∑
j=1
∑
l∈Lk
αljµkjxkj‖2 +
p∑
j=1
(
∑
l∈Lk
αlj(s
2
1j + µ
2
1j)− (
∑
l∈Lk
αlj)
2µ2kj)x
>
kjxkj
)
,
σ2βk =
∑p
j=1
∑
l∈Lk αlj(µ
2
kj + s
2
kj)∑p
j=1
∑
l∈Lk αlj
, αl =
∑p
j=1 αlj
p
,∀l ∈ {00, 10, 01, 11},
(S8)
where L1 = {10, 11}, L2 = {01, 11}. Clearly, σ2ek is equal to the its maximum likelihood
estimates adjusted by the variance of γkjβkj, update for σ
2
βk
is the weighted average of
posterior variance, where the weights are the posterior mean of γkj, and update for αl is the
average of all posterior mean of γkj. Derivation details for parameter updates in Gaussian
distribution (S16), and update equations (S21) and (S8) can be found later. The VBEM
algorithm (Algorithm S1) performs similarly to coordinate descent algorithm, which comes
from the factorization of variational distribution (S39). Hence, VBEM algorithm developed
here is scalable to ultra-high dimensions.
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4.1 The derivation of lower bound
The lower bound (8) of quantitative FGP model can be written as
L(q) =Eq[Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)]− Eq[log q(β1,β2,γ1,γ1)]. (S9)
Algebraically, the first term of lower bound (S9) is
Eq log[Pr(y1,y2,β1,β2,γ1,γ2|X1,X2;θ)]
=
2∑
k=1
(
− nk
2
log(2piσ2ek)−
yTk yk
2σ2ek
+
∑p
j=1 Eqj[γkjβkj]xTkjyk
σ2ek
− 1
2σ2ek
p∑
j=1
(
Eqj[γkjβkj]2xTkjxkj +
p∑
j′ 6=j
Eqjj′ [γkjβkjγkj′βkj′ ]xTkjxkj′
)
− p
2
log(2piσ2βk)−
1
2σ2βk
p∑
j=1
Eqjβ2kj
)
+
p∑
j=1
∑
l
Eqj[1([γ1j ,γ2j ]=l)] logαl
(S10)
where the variational expectations in (S10) are listed as below
Eqj[γkjβkj] =
∑
l∈Lk
αljµ1j,
Eqj[γkjβkj]2 =
∑
l∈Lk
αlj(µ
2
kj + s
2
kj),
Eqjj′ [γkjβkjγkj′βkj′ ] =
∑
l∈Lk
αljµ1j
∑
l∈Lk
αlj′µ1j′ ,
Eqjβ2kj =
∑
l∈Lk
αlj(µ
2
kj + s
2
kj) +
∑
l∈L/Lk
αljσ
2
β1
,
Eqj[1([γ1j ,γ2j ]=l)] = αlj.
(S11)
The second term of lower bound (S9) is the entropy of posterior distribution.
− Eq[log q(β1,β2,γ1,γ2)]
=−
p∑
j=1
Eqj[log q(β1j, β2j, γ1j, γ2j)]
=
2∑
k=1
(p
2
log σ2βk +
1
2
p∑
j=1
∑
l∈Lk
αlj log
s2kj
σ2βk
)
−
p∑
j=1
∑
l∈L
αlj logαlj
(S12)
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Obviously, taking some simplification, we can derive the analytical from of lower bound
L(q)
=
2∑
k=1
(
− nk
2
log(2piσ2ek)−
‖yk −
∑p
j=1
∑
l∈Lk αljµkjxkj‖2
2σ2ek
− 1
2σ2ek
p∑
j=1
Var[γkjβkj]xTkjxkj
)
−
p∑
j=1
∑
l
αlj(log
αlj
αl
)
+
1
2
2∑
k=1
p∑
j=1
∑
l∈Lk
αlj
(
log
s2kj
σ2βk
− µ
2
kj + s
2
kj
σ2βk
+ 1
)
− p log(2pi)− p
(S13)
where
Var[γkjβkj] =(
∑
l∈Lk
αlj)(µ
2
kj + s
2
kj)− (
∑
l∈Lk
αlj)
2µ2kj. (S14)
4.2 The derivation of posterior distribution
We derive the variational posterior distribution by maximizing the lower bound (S13). The
derivative function with respective to µkj and s
2
kj are
∂L(q)
∂µkj
=
(yk −
∑p
j=1
∑
l∈Lk αljµkjxkj)
>∑
l∈Lk αljxkj
σ2ek
−
∑
l∈Lk αljµkj − (
∑
l∈Lk αlj)
2µkj
σ2ek
−
∑
l∈Lk
αlj
µkj
σ2βk
= 0,
∂L(q)
∂s2kj
=−
∑
l∈Lk αljx
>
kjxkj
2σ2ek
+
1
2
∑
l∈Lk
αlj(
1
s2kj
− 1
σ2βk
) = 0.
(S15)
It is obvious to obtain
µkj =
x>kjyk −
∑p
i 6=j
∑
l∈Lk αliµkix
>
kjxki
x>kjxkj +
σ2ek
σ2βk
, s2kj =
σ2ek
x>kjxkj +
σ2ek
σ2βk
. (S16)
The posterior distribution is
q(β1j, β2j, γ1j, γ2j) =
2∏
k=1
(
fkj(βkj)
γkjf0(βkj)
1−γkj
)∏
l
α
1([γ1j ,γ2j ]=l)
lj . (S17)
45
4.3 The estimation of model parameters
Then we derive the updating formula of αlj and θ by maximizing the lower bound (S13).
For the updating formula of posterior αlj, we adopt to the lagrange multiplier approach.
Lag(q) = L(q) +
p∑
j=1
λj(1−
∑
l
αlj) (S18)
The derivative with respect to α00j and α01j are
∂Lag(q)
∂α00j
= − logα00j − 1− λj + logα00 = 0
∂Lag(q)
∂α01j
=
1
2
µ2jx
T
2jy2 −
1
2
(s22j + µ
2
2j)(
1
s22j
− 1
σ2β2
)− µ2j(
xT2jy2
2
− µ2j
s22j
)
− logα01j − 1− λj + logα01 + 1
2
(
log
s22j
σ2β2
− µ
2
2j + s
2
2j
σ2β2
+ 1
)
= 0 (S19)
We can obtain the following equation using last equation (S19).
log
α01j
α00j
= log
α01
α00
+
1
2
log
s22j
σ2β2
+
µ22j
2s22j
(S20)
Similarly, we can get the other three equations. After some algebra, they can expressed in
the way of equation 16 in the text.
A00j = logα00 +
1
2
log σ2β1 +
1
2
log σ2β2 ,
A10j = logα10 +
1
2
log s21j +
1
2
log σ2β2 +
µ21j
2s21j
,
A01j = logα01 +
1
2
log σ2β1 +
1
2
log s22j +
µ22j
2s22j
,
A11j = logα11 +
1
2
log s21j +
1
2
log s22j +
µ21j
2s21j
+
µ22j
2s22j
,
αlj =
exp(Alj)∑
l∈{00,10,01,11} exp(Alj)
. (S21)
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Next, we maximize the lower bound with respect to σ2ek .
∂L(q)
∂σ2ek
=− nk
2σ2ek
+
‖y −∑pj=1∑l∈Lk αljµkjxkj‖
2σ4ek
+
1
2σ4ek
p∑
j=1
Var[γkjβkj]xTkjxkj = 0
(S22)
which yields a maximum at
σ2ek =
1
nk
(
‖yk −
p∑
j=1
∑
l∈Lk
αljµkjxkj‖2 +
p∑
j=1
Var[γkjβkj]x>kjxkj
)
(S23)
Then, we maximize lower bound with respect to σ2βk .
∂L(q)
∂σ2βk
=
1
2
p∑
j=1
∑
l∈Lk
αlj
(
− 1
σ2βk
+
µ2kj + s
2
kj
σ4βk
)
= 0 (S24)
which has a maximum at
σ2βk =
∑p
j=1
∑
l∈Lk αlj(µ
2
kj + s
2
kj)∑p
j=1
∑
l∈Lk αlj
(S25)
At last, it is obvious to get updating equation of αl by lagrange multiplier approach
αl =
∑p
j=1 αlj
p
, ∀l ∈ {00, 10, 01, 11}, (S26)
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Algorithm 1: Variational EM algorithm to solve the quantitative FGP model
1 Initialization: {αkj, µkj}j=1,...,p, σ2βk , σ2ek . Let y˜k =
∑p
j=1
∑
l∈Lk αljµkjxkj with
L1 = {10, 11}, L2 = {01, 11}.
2 repeat
3 for j = 1 : p do
4 for k = 1 : 2 do
5 y˜k ← y˜k −
∑
l∈Lk αljµkjxkj
6 s2kj ←
σ2ek
x>kjxkj+
σ2ek
σ2
βk
.
7 µkj ← x
>
kjyk−
∑p
i 6=j Ei[γkiβki]x
>
kjxki
x>kjxkj+
σ2ek
σ2
βk
8 αlj ← exp(Alj)∑
l∈{00,10,01,11} exp(Alj)
, where Alj are defined in expression (S21)
9 y˜k ← y˜k +
∑
l∈Lk αljµkjxkj
10 end
11 end
12 σ2ek ← 1nk
(
‖yk −
∑p
j=1
∑
l∈Lk αljµkjxkj‖2 +
∑p
j=1(
∑
l∈Lk αlj(s
2
kj + µ
2
kj)−
(
∑
l∈Lk αlj)
2µ2kj)x
>
kjxkj
)
13 σ2βk ←
∑p
j=1
∑
l∈Lk αlj(µ
2
kj+s
2
kj)∑p
j=1
∑
l∈Lk αlj
14 αl ←
∑p
j=1 αlj
p
,∀l ∈ {00, 10, 01, 11}
15 until Converge;
48
5 Proof detail for the binary-trait model
5.1 Accommodating case-control data
Suppose that we have GWAS datasets {y1,X1,Z1} and {y2,X2,Z2} for a case-control study
with n1 and n2 samples, respectively. All settings remain the same to the quantitative traits
except that yk ∈ Rnk×1 is the vector for disease status taking values -1 and 1 for study k
and Zk = [zk1, . . . , zkp0 ] ∈ Rnk×p0 is a matrix for p0 covariates. Then conditional on observed
genotype Xk, hidden status γ, and effects βk, we have
yk|Xk,Zk,βk,γk,φk ∼ Ber(δk), (S27)
where δk = [δk1, . . . , δknk ]
>, δki
(
= Pr(yki = 1|X,βk,γk) = 11+e−ykiηki
)
is the sigmoid function
of linear predictor ηki, i is the index for individuals, ηk(= [ηk1, . . . , ηknk ]
> ∈ Rnk×1) is the lin-
ear predictor of the all individuals in study k such that ηk =
∑p0
j=1 zkjφkj +
∑p
j=1 γkjβkjxkj.
Note that φk is a vector of fixed effects including intercept in the model. Here, we in-
clude fixed-effect covariates in the binary studies to adjust population stratification in
samples. β and γ are effect sizes and indicator variables as defined in Section 2. Let
θ = {σ2β1 , σ2β2 ,φ1,φ2,α} be the collection of model parameters. The probabilistic model can
be written as
Pr(y1,y2,β1,β2,γ1,γ2|X1,Z1,X2,Z2;θ) =
2∏
k=1
(
Pr(yk|Xk,Zk,βk,γk;θ)Pr(βk|θ)
)
Pr(γ|θ).
(S28)
Note that we take coefficients for covariates (Z1 and Z2) as fixed effects, which are included
in parameter space θ. Marginalizing over latent variables (β1,β2,γ1,γ2), we can get the
marginal likelihood. The primary difficulty for the binary model (S28) comes from the
evaluation of sigmoid function δki. As there is no convenient conjugate prior for sigmoid
function, it is not analytically feasible to compute the full posterior over the parameter
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space. To overcome this limitation,, we use the Bohning bound [Bo¨hning, 1992]. Here, we
first derive a lower bound of the complete-data likelihood as follows
Pr(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2,θ)
≥
(
2∏
k=1
B(yk|Xk,Zk,βk,γk;θ)Pr(βk;θ)
)
Pr(γ;θ)
=h(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2; θ˜),
(S29)
whereB(yk|Xk,Zk,βk,γk; θ˜)
(
=
∏nk
i=1 exp(−12aη2kiy2ki + (1 + bki)ηkiyki − cki)
)
denotes the prod-
uct of lower bound of sigmoid functions with a = 1/4, bkn = aψkn − (1 + e−ψkn)−1 and
ckn =
1
2
aψ2kn − (1 + e−ψkn)−1ψkn + log(1 + eψkn), and θ˜ = {σ2β1 , σ2β2 ,φ1,φ2,α,ψ1,ψ2} is the
new parameter which combines the model parameters θ with variational parameters ψ1,ψ2.
Using Jensen’s inequality and the lower bound of complete-data likelihood (S29), we have
the following lower bound
log Pr(y1,y2|X1,X2,Z1,Z2,θ)
= log
∑
β1,β2,γ1,γ2
Pr(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2,θ)
≥ log
∑
β1,β2,γ1,γ2
h(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2,θ)
≥Eq[log h(y1,y2,β1,β2,γ1,γ2|X1,X2,Z1,Z2; θ˜)]− Eq[log q(β1,β2,γ1,γ2)] := L(q),
(S30)
where the first inequality is based on Bohning bound and the second one follows from Jensen’s
inequality as in lower bound. By maximizing the lower bound (S32) with respect to µkj and
s2kj, we can again obtain the variational distribution in the same fashion as expression (S39).
With some algebra, we have
µkj =
x>kjy
∗
k − axTkjZkφk − a
∑p
j′ 6=j
∑
l∈Lk αlj′µkj′x
>
kj′xkj
ax>kjxkj +
1
σ2βk
, s2kj =
1
ax>kjxkj +
1
σ2βk
, (S31)
where y∗k
(
= ((1 + bk1)yk1, · · · , (1 + bknk)yknk)>
)
is the working response and αlj is the log
posterior odds of being l in expression (S21). The difference only lies in the updating
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equation for the posterior mean µkj, which uses working response y
∗
k and the re-weighting
design matrix a1/2Z and a1/2X. As a is a constant, there is no additional computational
burden to evaluate the re-weighting design. Once we loop through all variational parameters,
other parameters (θ˜) can be updated by maximizing the lower bound while keep variational
distribution q fixed, i.e. , ∂L
∂θ˜
= 0.
5.2 The derivation of lower bound
As the definition of lower bound for binary trait model is
L(q) =Eq[log h(y1,y2,β1,β2,γ1,γ2|X1,X2; θ˜)]− Eq[log q(β1,β2,γ1,γ2)] (S32)
We can derive the analytical form of lower bound by evaluate these two expectation. The
first expectation of lower bound (S32) is
Eq[log h(y1,y2,β1,β2,γ1,γ2|X1,X2; θ˜)]
=
2∑
k=1
(
−
nk∑
n=1
ckn +
nk∑
n=1
(1 + bkn)yknz
T
knφk −
a
2
nk∑
n=1
(yknz
T
knφk)
2
+
p∑
j=1
Ej[γkjβkj]xTkjy∗k − a
p∑
j=1
Ej[γkjβkj]xTkjZkφk
− a
2
p∑
j=1
Ej[γkjβkj]2xTkjxkj −
a
2
p∑
j=1
p∑
j′ 6=j
Eqjj′ [γjβkjγkj′βkj′ ]xTkjxkj′
− 0.5a
p∑
j=1
Var[γkjβkj]xTkjxkj
− p
2
log(2piσ2β1)−
1
2σ2βk
p∑
j=1
Eqjβ2kj
)
+
p∑
j=1
∑
l
Eqj[1([γ1j ,γ2j ]=l)] logαl
(S33)
Where zkn denotes the nth row of covariates matrix Zk, the outcome of these expectations in
the above equation is the same as the expectations in the previous equation (S11). Besides,
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the analytical form of the second term in the equation (S32) is also the same as the second
term of lower bound (S9). The only difference is that the mean µkj and variance skj are
defined in the equation (S16). As we derive the first term and second term of the lower
bound, the whole lower bound can be obviously obtained by adding them together.
L(q) =
2∑
k=1
(
mTkX
T
k y
∗
k − amTkXTkZkφk − 0.5amTkXTkXkmk
− 0.5a
p∑
j=1
Var[γkjβkj]xTkjxkj −
nk∑
n=1
ckn + y
∗>
k Zkφk − 0.5aφTkZTkZkφk
)
−
p∑
j=1
∑
l
αlj(log
αlj
αl
) +
1
2
2∑
k=1
p∑
j=1
∑
l∈Lk
αlj
[
log
s2kj
σ2βk
− µ
2
kj + s
2
kj
σ2βk
+ 1
]
− p log(2pi)− p
(S34)
where
mk = (
∑
l∈Lk
αl1µk1, · · · ,
∑
l∈Lk
αlpµkp)
T
Var[γkjβkj] =
∑
l∈Lk
αlj(µ
2
1j + s
2
1j)− (
∑
l∈Lk
αlj)
2µ21j
(S35)
5.3 The derivation of posterior distribution
We derive the variational posterior distribution by maximizing the lower bound (S34). The
derivative function with respective to µkj and s
2
kj are
∂L(q)
∂µkj
=
∑
l∈Lk
αljx
>
kjy
∗
k − a
∑
l∈Lk
αljx
T
kjZkφk − a
p∑
j=1
(
∑
l∈Lk
αlj)
2µkjx
>
kjxkj
− a
(∑
l∈Lk
αljµkj − (
∑
l∈Lk
αlj)
2µkj
)
x>kjxkj −
∑
l∈Lk
αlj
µkj
σ2βk
= 0
(S36)
∂L(q)
∂s2kj
= −a
∑
l∈Lk αljx
>
kjxkj
2
+
1
2
∑
l∈Lk
αlj(
1
s2kj
− 1
σ2βk
) = 0 (S37)
It is obvious to obtain
µkj =
x>kjy
∗
k − axTkjZkφk − a
∑p
i 6=j
∑
l∈Lk αliµkix
>
kjxki
ax>kjxkj +
1
σ2βk
, s2kj =
1
ax>kjxkj +
1
σ2βk
(S38)
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The posterior distribution is
q(β1j, β2j, γ1j, γ2j) =
2∏
k=1
fkj(βkj)
γkjf0(βkj)
1−γkj
∏
l
α
1([γ1j ,γ2j ]=l)
lj (S39)
5.4 The estimation of model parameters
Then we want to derive the updating formula of αlj and θ. The technique to get the updating
formula of αlj, σ
2
βk
and αl is similar and the updating equation is almost the same as that
in the quantitative trait model.Here we discuss the updating equation of ψk and φk. We
maximize lower bound with respect to ψk
L(q)
∂ψkn
=
∂mTkX
T
k y
∗
k
∂ψkn
− ∂ckn
∂ψkn
+
∂y∗Tk Zkφk
∂ψkn
= 0 (S40)
which gets the maximum at
ψkn = yn
p∑
j=1
∑
l∈Lk
αljµkjxknj + ynz
T
knφk (S41)
Then, we maximize lower bound with respect to φk
∂L(q)
∂φk
= ZTk y
∗
k − aZTkXkmk − aZTkZkφk = 0 (S42)
which obtain the maximum at
φk = (Z
T
kZk)
−1
(1
a
ZTk y
∗
k − ZTkXkmk
)
(S43)
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Algorithm 2: Variational EM algorithm to solve the FGP model in case-control studies
1 Initialization: {αkj, µkj}j=1,...,p, σ2βk ,φk,ψk. Let y˜k =
∑p
j=1
∑
l∈Lk αljµkjxkj with
L1 = {10, 11}, L2 = {01, 11},a = 14 .
2 repeat
3 for n = 1 : nk do
4 for k = 1 : 2 do
5 bkn ← aψkn − (1 + e−ψkn)−1
6 ckn ← 12aψ2kn − (1 + e−ψkn)−1ψkn + log(1 + eψkn)
7 end
8 end
9 for j = 1 : p do
10 for k = 1 : 2 do
11 y˜k ← y˜k −
∑
l∈Lk αljµkjxkj
12 s2kj ← 1ax>kjxkj+ 1σ2
βk
.
13 µkj ← x
>
kjy
∗
k−ax>j Zkφk−a
∑p
i 6=j Ei[γkiβki]x
>
kjxki
axTkjxkj+
1
σ2
βk
14 αlj ← exp(Alj)∑
l∈{00,10,01,11} exp(Alj)
, where Alj are defined in expression (S21)
15 y˜k ← y˜k +
∑
l∈Lk αljµkjxkj
16 end
17 end
18 σ2βk ←
∑p
j=1
∑
l∈Lk αlj(µ
2
kj+s
2
kj)∑p
j=1
∑
l∈Lk αlj
19 αl ←
∑p
j=1 αlj
p
,∀l ∈ {00, 10, 01, 11}
20 φk ← (ZTkZk)−1
[
1
a
ZTk y
∗
k − ZTk y˜k
]
21 ψkn ← yn
∑p
j=1
∑
l∈Lk αljµkjxknj + ynz
T
knφk
22 until Converge;
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